Patrick R. Coyle
GTN Thought Leader & Commercialization Strategist
Patrick R. Coyle is a life sciences executive, GTN thought leader, finance strategist, and commercialization transformation advisor with nearly twenty years helping pharmaceutical manufacturers improve patient access, optimize channel performance, and strengthen enterprise profitability.
From global product launches and GTN transformation initiatives to commercialization strategy and healthcare revenue intelligence, Patrick has spent his career connecting patient journey outcomes with financial performance.
Healthcare has never had more organizations working to improve patient outcomes. Yet it has also never been more fragmented.
Our mission: build a trusted community where every stakeholder learns from one another and collaborates on solutions that improve the patient journey.
Patients and profitability are not competing priorities. Sustainable innovation depends on both.
The Ecosystem
Patients & Caregivers
Lived experience. Real-world barriers.
Patient Advocacy Orgs
Amplify patient voices.
Healthcare Providers
Clinical insight. Workflow reality.
Pharma Manufacturers
Patient-centric commercialization & affordability.
Tech & Service Providers
Transparency. Efficiency. Innovation.
Cross-Functional Teams
NextGen GTN™
Education & executive workshops for cross-functional alignment.
Novus Proximus LLC
Turns ideas into channel strategy & transformation.
My career has been shaped by a commitment to both: building financially sound organizations that deliver life-changing therapies to the patients who need them most.
My Bayer Journey: Finance Partner to Innovation (2008–2016)
Supporting Alpha Radium-223 from Clinical Development Through Global Commercialization
Clinical Development Finance
Phase 2b Development- Trial financial planning
- Investment decisions
Pivotal Trial Finance Partner
Phase 3 Development- Phase 3 program support
- Risk-adjusted valuation
Launch Readiness Finance
US Launch Preparation- Market access planning
- Revenue forecasting
Global Commercialization Finance
Global Launch Sequencing- Launch prioritization
- Global forecasting
Redesigning the Patient Journey.
Improving Outcomes. Changing Lives.
Eisai
JOURNEY
Two TKIs. One Mission.
From sorafenib to lenvatinib
Sorafenib
Tyrosine kinase inhibitortwo vantage points Bringing a therapy to market, then making sure patients could reach it.
Lenvatinib
Tyrosine kinase inhibitorWhat 25 Years Taught Me About Patients and Profitability
Every Prescription Begins With Hope.
A provider writes a prescription. The patient leaves the office expecting therapy to follow.
Between those two moments sits a system that decides whether it does.
For nearly twenty years, I've worked at the intersection of pharmaceutical finance, patient access, commercialization, and operational strategy, and I've seen the same reality repeatedly:
Patients are lost long before therapy begins.
Manufacturers struggle to understand where profitability is leaking across increasingly complex commercialization models. These are not separate problems — they are two sides of the same system.
Patients + Profitability™ was created to help organizations understand both.
That is the work. That is the mission.
That is Patients + Profitability™.
What I Learned
Partnerships Matter
Support Improves Persistence
Finance Can Quantify Impact
Architecting Strategic Financial Advantage
Rebuilding the finance organization
Sequencing a multi-year rebuild so that each step makes the next one possible. See Simplify, Standardize, Automate, Measure and Structure Instead of Spend.
Gross-to-Net and what sits upstream of it
Finding where the number was decided, which is rarely where it is reported. See Finance Should Own the Number and Not the Operating Model, Every Function Green, the Aggregate Red, and The Leak I Built.
Launch and access economics
Forecasting against the patients a label actually reaches, and building the operating model before the first shipment. See Can We Actually Find Them, Building the Road to Revenue, and One Method, Eight Countries.
Frequently asked questions about Patrick R. Coyle
Who is Patrick R. Coyle?
Patrick R. Coyle is a pharmaceutical commercialization and Gross-to-Net advisor with more than 25 years of finance and commercial leadership. He is the founder and CEO of Novus Proximus LLC, the creator of the Patients + Profitability™ philosophy, The 10 Exits of Therapy™ and The Silent Leak™, and the host of the Patients + Profitability™ podcast.
Where has Patrick worked?
Patrick's career includes Bayer, Novartis, Insmed, Eisai Americas, where he served as Vice President and Chief Financial Officer, IQVIA's Gross-to-Net advisory practice, and Baker Tilly, where he led Gross-to-Net risk advisory. He moved into pharma from IT and finance and has spent 18 years directly in the industry.
What is Novus Proximus?
Novus Proximus LLC is the healthcare commercialization advisory firm Patrick founded. It works with life sciences companies across the product lifecycle, from pre-launch readiness through in-market optimization and loss of exclusivity, on Gross-to-Net strategy, patient access, launch readiness and finance transformation.
What does Patrick write and speak about?
Gross-to-Net, patient access, patient support services, copay and affordability, specialty pharmacy and distribution, launch forecasting, accrual design and finance transformation. He has moderated, spoken or served on panels at more than 25 industry conferences since 2014 and publishes first on patrickrcoyle.com before syndicating to LinkedIn and Substack.
How can I work with Patrick?
Through Novus Proximus advisory engagements, Commercialization Alignment Labs™, executive education such as Finance Fundamentals for Commercial Leaders™, speaking, or as a guest on the Patients + Profitability™ podcast. The Contact page routes each request to the right starting point.
Definitions of the terms used here: the Patients + Profitability™ Glossary.